3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
40
Kidney Neoplasms
30
Melanoma
25
Prostatic Neoplasms
24
Breast Neoplasms
18
Wilms Tumor
16
Neoplasm Metastasis
16
Ovarian Neoplasms
14
Carcinoma, Non-Small-Cell Lung
12
Testicular Neoplasms
11
Multiple Myeloma
11
Uterine Cervical Neoplasms
10
Sarcoma
9
Pancreatic Neoplasms
9
Neuroblastoma
9
Testicular Germ Cell Tumor
8
Lymphoma, Follicular
8
Lymphoma
8
Lung Neoplasms
8
Hodgkin Disease
8
Carcinoma, Hepatocellular
8
Triple Negative Breast Neoplasms
7
Neoplasms, Plasma Cell
7
Neoplasms
7
Lymphoma, Non-Hodgkin
7
Lymphoma, Mantle-Cell
7
Lymphoma, Large-Cell, Immunoblastic
7
Lymphoma, Large B-Cell, Diffuse
7
Leukemia, Myeloid, Acute
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Interventions
Nivolumab
14
Ipilimumab
11
Specimen Handling
10
CTLA-4 Antigen
7
pembrolizumab
6
cabozantinib
6
Sunitinib
6
Magnetic Resonance Spectroscopy
6
Axitinib
5
pazopanib
4
Biopsy
4
Radiosurgery
3
lenvatinib
2
fludarabine
2
Everolimus
2
Blood Specimen Collection
2
tivozanib
1
sodium-iodide symporter
1
sitravatinib
1
belzutifan
1
atezolizumab
1
aldesleukin
1
Zoledronic Acid
1
Tissue Banks
1
Selenomethionine
1
Radiotherapy
1
Radiopharmaceuticals
1
Pluvicto
1
Nephrectomy
1
Molecular Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Clear-cell metastatic renal cell carcinoma
×
Cyclophosphamide
×
Genitourinary
×
Clear all
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled